Press Releases / Stock Exchange Intimation

Date Title   Report

16 Jun 2024 Intimation under Reg 39 (3) of LODR – Vibhishanan V PDF 2.55 MB
14 Jun 2024 Intimation under Regulation 30 of SEBI LODR PDF 270 KB
23 May 2024 Newspaper Advertisement – Audited Financial Results for quarter and financial year ended March 31, 2024 PDF 1.28 MB
22 May 2024 Observation Letters from BSE & NSE PDF 2.06 MB
22 May 2024 Disposal of Corporate Insolvency Process against Strides Alathur Private Limited PDF 346 KB
22 May 2024 Outcome of Board Meeting – Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 2024 & Recommendation of Dividend PDF 4.89 MB
22 May 2024 Outcome of Board Meeting – Press Release & Earnings Presentation PDF 1.54 MB
22 May 2024 Outcome of Board Meeting – Change in Board composition and Management PDF 376 KB
22 May 2024 Outcome of Board Meeting - Allotment of Shares PDF 288 KB
22 May 2024 Outcome of Board Meeting - Grant of ESOP PDF 295 KB
22 May 2024 Strides receives USFDA approval for Sucralfate Oral Suspension, 1gm/10 mL PDF 444 KB
21 May 2024 Intimation under Reg 39 (3) of LODR – Rajagopalan J PDF 713 KB
10 May 2024 Strides receives USFDA approval for Sevelamer Carbonate Tablets, 800 mg PDF 1.11 MB
06 May 2024 Intimation under Reg 39 (3) of LODR – K Murali PDF 730 KB
30 Apr 2024 Voting Results of Postal Ballot pursuant to Reg. 44 of SEBI Listing Regulations – Appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company PDF 2.35 MB
29 Apr 2024 Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) PDF 749 KB
09 Apr 2024 Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg PDF 455 KB
06 Apr 2024 Completion of US-FDA Inspection at the Formulations Facility of Strides Alathur Private Limited, a wholly owned subsidiary of the Company PDF 249 KB
29 Mar 2024 Newspaper Advertisement - Notice of Postal Ballot dated March 27, 2024 PDF 1.00 MB
28 Mar 2024 Outcome of Appeal at Hon’ble National Company Law Appellate Tribunal, New Delhi – Corporate Insolvency Process against Strides Alathur stands stayed PDF 260 KB
28 Mar 2024 Notice of Postal Ballot dated March 27, 2024 PDF 586 KB
26 Mar 2024 Intimation under Regulation 30 of SEBI LODR regarding Strides Alathur PDF 320 KB
18 Mar 2024 Intimation under Reg 39 (3) of LODR - Venkat Seetharama Rao Teegala PDF 318 KB
08 Mar 2024 Newspaper Publication – Hearing of Petition in the matter of Scheme of Amalgamation between Strides Alathur Private Limited and the Company PDF 2.61 MB
05 Mar 2024 Strides receives USFDA approval for Gabapentin Tablets USP, 600 mg and 800 mg PDF 596 KB
02 Feb 2024 Intimation under Regulation 30 of SEBI LODR – Investors Presentation PDF 2 MB
02 Feb 2024 Intimation under Regulation 30 of SEBI LODR – Update on divestment of Eris Pharma GmbH, Germany PDF 252 KB
31 Jan 2024 Newspaper Advertisement – Unaudited Financial Results for quarter and nine months ended December 31, 2023 PDF 1.22 MB
30 Jan 2024 Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 2023 PDF 642 KB
30 Jan 2024 Strides reports strong Q3FY24 Revenue and EBITDA PDF 1.63 MB
30 Jan 2024 Appointment of Mr. Ameet P Hariani as Independent Director of the Company PDF 275 KB
30 Jan 2024 Intimation under Regulation 30 of SEBI Listing Regulations – Corporate Guarantees on behalf of Stelis PDF 394 KB
30 Jan 2024 Allotment of Shares PDF 284 KB
25 Jan 2024 Strides receives USFDA approval for Pregabalin Capsules PDF 404 KB
23 Jan 2024 Intimation under Reg 39 (3) of LODR - Haresh Dave & Karesh Dave PDF 711 KB
11 Jan 2024 Intimation under Regulation 30 of SEBI LODR – Divestment of Eris Germany PDF 432 KB
08 Jan 2024 Intimation under Reg 39 (3) of LODR - Geeta K Doshi PDF 878 KB
08 Jan 2024 Intimation under Reg 39 (3) of LODR - Krishna Kishore Busetty PDF 475 KB
05 Jan 2024 Intimation under Regulation 30 of SEBI LODR – Acquisition of additional stake in Neviton PDF 346 KB
02 Jan 2024 Intimation under Regulation 30 of SEBI LODR – Investment in AMP Energy PDF 300 KB
Date Title   Report

29 Dec 2023 Intimation under Regulation 30 of SEBI LODR – Update on Sale of Manufacturing Facility in Singapore PDF 237 KB
29 Dec 2023 Intimation under Reg 39 (3) of LODR PDF 525 KB
26 Dec 2023 Intimation under Reg 39 (3) of LODR PDF 309 KB
23 Dec 2023 Update on Stelis Biopharma’s transaction with Syngene for sale of Stelis’ Unit 3 Multi-Model Facility in Bengaluru PDF 210 KB
21 Dec 2023 Intimation under Regulation 30 of SEBI LODR – Matter relating to Trinity, South Africa PDF 304 KB
19 Dec 2023 Intimation under Reg 39 (3) of LODR PDF 316 KB
01 Dec 2023 Strides associate company - Stelis Biopharma announces closure of its transaction with Syngene International Limited PDF 286 KB
01 Dec 2023 Strides launches Icosapent Ethyl Acid Soft Gel Capsules in partnership with Amneal PDF 539 KB
28 Nov 2023 Intimation under Reg 39 (3) of LODR PDF 413 KB
23 Nov 2023 Strides receives USFDA approval for Generic Suprep® Bowel Prep Kit PDF 451 KB
21 Nov 2023 Strides receives USFDA approval for Levetiracetam Oral Solution PDF 406 KB
31 Oct 2023 Newspaper Advertisement – Unaudited Financial Results for quarter and half year ended September 30, 2023 PDF 1 MB
31 Oct 2023 Intimation under Reg 39 (3) of LODR PDF 377 KB
30 Oct 2023 Change in SMP PDF 398 KB
30 Oct 2023 Q2 – Statement of Deviation/Variation for the quarter ended September 30, 2023 PDF 457 KB
30 Oct 2023 Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2023 PDF 738 KB
30 Oct 2023 Allotment of Shares PDF 334 KB
30 Oct 2023 Strides reports Strong Q2FY24 Performance - Revenues at ₹ 10,264m and EBITDA at ₹ 1,801m PDF 2 MB
27 Oct 2023 Strides announces sale of manufacturing facility in Singapore for a consideration of $15m PDF 500 KB
25 Oct 2023 Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) PDF 367 KB
25 Oct 2023 Intimation under Reg 39 (3) of LODR PDF 335 KB
20 Oct 2023 Intimation under Regulation 30 of SEBI Regulations, 2015 (Allotment of shares) PDF 334 KB
04 Oct 2023 Strides receives USFDA approval for Efavirenz, Emtricitabine & Tenofovir Disoproxil Fumurate tablets PDF 385 KB
03 Oct 2023 Strides receives USFDA approval for Icosapent Ethyl Capsules - Updated Press Release PDF 450 KB
25 Sep 2023 Transaction amongst wholly-owned subsidiaries PDF 305 KB
25 Sep 2023 Intimation of Scheme of Arrangement pursuant to Regulation 30 of SEBI Listing Regulations PDF 2 MB
25 Sep 2023 Investor call link PDF 325 KB
23 Sep 2023 Strides receives USFDA approval for Icosapent Ethyl Capsules PDF 447 KB
15 Sep 2023 Strides receives tentative USFDA approval for Dolutegravir/ Lamivudine/ Tenofovir Disproxil Fumurate tablets PDF 448 KB
14 Sep 2023 Strides receives tentative USFDA approval for Dolutegravir tablets. PDF 505 KB
09 Sep 2023 Strides receives USFDA approval for Sevelamer Carbonate for Oral Suspension. PDF 442 KB
07 Sep 2023 Intimation under Regulation 30 of SEBI LODR - Internal Restructuring of Strides Pharma Services Private Limited, a group entity. PDF 298 KB
06 Sep 2023 Intimation under Reg 39 (3) of LODR PDF 426 KB
01 Sep 2023 Intimation under Regulation 30 of SEBI Regulations, 2015 (Change in Senior Management) PDF 315 KB
30 Aug 2023 Strides receives USFDA approval for Mycophenolate Mofetil for Oral Suspension PDF 447 KB
30 Aug 2023 Outcome of 32nd Annual General Meeting of the Company PDF 884 KB
29 Aug 2023 Intimation under Regulation 30 of SEBI Listing Regulations – Corporate Guarantees on behalf of Stelis PDF 426 KB
29 Aug 2023 Intimation under Reg 39 (3) of LODR PDF 311 KB
28 Aug 2023 Proceedings of AGM PDF 497 KB
22 Aug 2023 Intimation under Reg 39 (3) of LODR PDF 385 KB
16 Aug 2023 Intimation under Regulation 30 of SEBI Listing Regulations (CGs and Litigations) PDF 810 KB
05 Aug 2023 Newspaper Publication titled ‘Notice of 32nd Annual General Meeting, Remote E-Voting and Cut-Off Date’ PDF 1.63 MB
04 Aug 2023 Notice of the 32nd Annual General Meeting and Annual Report for FY 2022-23 PDF 6 MB
04 Aug 2023 Submission of Business Responsibility & Sustainability Report for FY23 PDF 605 KB
03 Aug 2023 Unaudited Financial Results for the quarter ended June 30, 2023 PDF 4 MB
03 Aug 2023 Intimation under Reg 39 (3) of LODR PDF 377 KB
02 Aug 2023 Intimation under SEBI (Prohibition of Insider Trading) Regulations, 2015 PDF 466 KB
02 Aug 2023 Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations PDF 385 KB
02 Aug 2023 Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2023 PDF 629 KB
02 Aug 2023 Strides reports highest ever EBITDA, INR 1,686m in Q1FY24 PDF 2 MB
28 July 2023 Outcome of Postal Ballot PDF 1 MB
19 July 2023 Intimation under Reg 39 (3) of LODR PDF 297 KB
12 July 2023 Intimation under Reg 39 (3) of LODR PDF 381 KB
07 July 2023 Allotment of shares under Strides ESOP Plan 2016 PDF 1 MB
04 July 2023 Stelis Biopharma enters into a binding term sheet with Syngene International Limited to divest its Unit 3 multi-modal facility for a gross consideration of INR 7,020 million PDF 1 MB
29 June 2023 Intimation under Reg 39 (3) of LODR PDF 301 KB
28 June 2023 Intimation under Reg 39 (3) of LODR PDF 301 KB
27 June 2023 Newspaper Advertisement - Notice of Postal Ballot dated May 25, 2023 PDF 1 MB
26 June 2023 Notice of Postal Ballot dated May 25, 2023 PDF 233 KB
26 June 2023 Intimation under Reg 39 (3) of LODR PDF 382 KB
23 June 2023 Intimation under Reg 39 (3) of LODR PDF 369 KB
16 June 2023 Intimation under Reg 39 (3) of LODR PDF 364 KB
30 May 2023 Annual Secretarial Compliance Report for the year ended March 31, 2023 PDF 723 KB
30 May 2023 Annual Secretarial Compliance Report for the year ended March 31, 2023 PDF 233 KB
25 May 2023 Disclosure of Related Party Transactions for the half year ended March 31, 2023 PDF 233 KB
25 May 2023 Disclosure of Related Party Transactions for the half year ended March 31, 2023 PDF 584 KB
25 May 2023 Grant of Options under Strides ESOP Plan 2016 PDF 298 KB
25 May 2023 Strides reports strong Q4FY23 results and lays the foundation for a promising FY24 PDF 2 MB
25 May 2023 Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 2023 PDF 826 KB
24 May 2023 Newspaper Adv - Notice for transferring of equity shares to IEPF PDF 350 KB
19 May 2023 Strides Puducherry facility receives Establishment Inspection Report (EIR) from USFDA confirming the reclassification of the site from Official Action Indicated (OAI) to Voluntary Action Indicated (VAI) PDF 263 KB
19 May 2023 Intimation under Reg 39 (3) of LODR PDF 365 KB
18 May 2023 Intimation of Board Meeting scheduled on May 25, 2023 PDF 325 KB
3 May 2023 Strides and Orbicular enter into a strategic partnership to jointly develop a range of nasal sprays PDF 3.3 MB
24 Apr 2023 Intimation under Reg 39 (3) of LODR PDF 368 KB
17 Apr 2023 Intimation under Reg 39 (3) of LODR PDF 417 KB
23 Mar 2023 Outcome of Postal Ballot PDF 3.3 MB
20 Mar 2023 Intimation under Reg 39 (3) of LODR PDF 432 KB
14 Mar 2023 Intimation pursuant to Regulation 31A of SEBl Listing Regulations PDF 458 KB
24 Feb 2023 Strides flagship facility in Bangalore receives USFDA inspection closure PDF 389 KB
23 Feb 2023 Intimation pursuant to Regulation 31A of SEBl Listing Regulations PDF 532 KB
16 Feb 2023 Intimation under Reg 39 (3) of LODR PDF 330 KB
06 Feb 2023 Notice of Postal Ballot – January 24, 2023 PDF 532 KB
06 Feb 2023 Outcome of Extraordinary General Meeting of the Company held on February 6, 2023 PDF 660 KB
06 Feb 2023 Proceedings of Extraordinary General Meeting of the Company held on February 6, 2023 PDF 422 KB
25 Jan 2023 Earnings call Audio link Dec qtr PDF 274 KB
24 Jan 2023 Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended Dec 31, 2022 PDF 3.81 MB
24 Jan 2023 Grant of Options under Strides ESOP Plan 2016 PDF 272 KB
23 Jan 2023 Earnings call intimation_Dec qtr PDF 565 KB
20 Jan 2023 Completion of the WHO PQ inspection at the Puducherry facility of the Company PDF 275 KB
18 Jan 2023 Stelis Biopharma’s flagship facility receives EIR from the USFDA on the successful closure of its inspection specific to Drug-Device Combination Products PDF 391 KB
13 Jan 2023 Notice of Extraordinary General Meeting scheduled to be held on February 6, 2023 PDF 499 KB
Date Title   Report

27 May 2022 Newspaper Adv - Notice for transferring of equity shares to IEPF PDF 342 KB
28 Dec 2022 Stelis Biopharma’s CDMO partner receives approval for a key ANDA from the USFDA PDF 389 KB
23 Dec 2022 Intimation under Reg 39 (3) of LODR PDF 367 KB
22 Dec 2022 Receipt of AUD 94 million on account of deferred consideration on the sale of the Company’s Australian operations in 2019 PDF 273 KB
12 Dec 2022 Intimation under Reg 39 (3) of LODR PDF 297 KB
1 Dec 2022 Intimation under Reg 39 (3) of LODR PDF 2.29 MB
28 Nov 2022 RPT Disclosure for the half year ended Sept 30, 2022 PDF 2.51 MB
18 Nov 2022 Strides receives USFDA approval for Potassium Chloride Oral Solution PDF 2.30 MB
16 Nov 2022 Earnings Call Audio link_Sept quarter PDF 2.20 MB
14 Nov 2022 Resignation of Mr. Deepak Calian Vaidya, Non-Executive Director PDF 2.21 MB
14 Nov 2022 Allotment of shares under Strides ESOP Plan 2016 PDF 2.21 MB
14 Nov 2022 Grant of Options under Strides ESOP Plan 2016 PDF 2.20 MB
14 Nov 2022 Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended Sept 30, 2022 PDF 4.82 MB
14 Nov 2022 Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis PDF 2.30 MB
11 Nov 2022 Earnings Call intimation_Sept quarter PDF 2.60 MB
21 Oct 2022 Intimation under Reg 39 (3) of LODR PDF 1.60 MB
19 Oct 2022 Intimation under Reg 39 (3) of LODR PDF 233 KB
16 Sep 2022 Allotment of Shares - Sep 16, 2022 PDF 395 KB
15 Sep 2022 Intimation under Reg 39 (3) of LODR PDF 1.90 MB
08 Sep 2022 Outcome of the 31st Annual General Meeting of the Company – Reappointment of Statutory Auditors PDF 311 KB
08 Sep 2022 Outcome of the 31st Annual General Meeting of the Company PDF 698 KB
08 Sep 2022 Proceedings of the 31st Annual General Meeting of the Company held on September 9, 2022 PDF 433 KB
08 Sep 2022 Allotment of Shares_Sep 8, 2022 PDF 243 KB
02 Sep 2022 Allotment of Shares_Sep 2, 2022 PDF 288 KB
01 Sep 2022 Stelis Biopharma’s flagship facility receives USFDA nod for Drug Product Capabilities PDF 409 KB
30 Aug 2022 Intimation under Reg 39 (3) of LODR PDF 303 KB
26 Aug 2022 Press release issued by Universal Corporation Ltd., a Strides Pharma Science Limited Enterprise titled “First African-manufactured medicine to prevent malaria in pregnant women and infants quality - approved by WHO” PDF 421 KB
18 Aug 2022 Notice of the 31st Annual General Meeting and Annual Report for FY 2021-22 PDF 5.16 MB
18 Aug 2022 Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules PDF 354 KB
08 Aug 2022 Strides announces successful completion of US FDA inspection at its Singapore facility PDF 376 KB
03 Aug 2022 Strides receives USFDA approval for Cyclosporine Softgel Capsules PDF 681 KB
02 Aug 2022 Intimation under Reg 39 (3) of LODR PDF 348 KB
30 Jul 2022 Earnings Call Audio link_June quarter PDF 310 KB
29 Jul 2022 Grant of Options under Strides ESOP Plan 2016 PDF 238 KB
29 Jul 2022 Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2022 PDF 2.8 MB
28 Jul 2022 Earnings Call intimation_June quarter PDF 587 KB
19 Jul 2022 Intimation under Reg 39 (3) of LODR PDF 381 KB
14 Jul 2022 Intimation under Reg 39 (3) of LODR PDF 443 KB
12 Jul 2022 Intimation under Reg 39 (3) of LODR PDF 299 KB
07 Jul 2022 Outcome of the Postal Ballot Notice dated May 24, 2022 PDF 5 MB
30 Jun 2022 Intimation under Reg 39 (3) of LODR PDF 209 KB
28 Jun 2022 Intimation under Reg 39 (3) of LODR PDF 300 KB
24 Jun 2022 Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine PDF 344 KB
17 Jun 2022 Intimation under Reg 39 (3) of LODR PDF 382 KB
16 Jun 2022 Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation PDF 354 KB
10 Jun 2022 Strides receives USFDA approval for Ibuprofen OTC Oral Suspension PDF 379 KB
08 Jun 2022 Disclosure of Related Party Transactions for half year ended March 31, 2022 PDF 432 KB
01 Jun 2022 Transcript of Earnings call PDF 417 KB
30 May 2022 Strides receives USFDA approval for Ibuprofen Oral Suspension PDF 314 KB
25 May 2022 Audio Recording of Earnings call pertaining to the Financial Results for the Quarter and Financial Year Ended March 31, 2022. PDF 233 KB
24 May 2022 Grant of Options under Strides ESOP Plan 2016 PDF 230 KB
24 May 2022 Outcome of Board Meeting - Disclosure under Regulation 30 of SEBI Listing Regulations PDF 5.6 MB
15 May 2022 Clarification on news item appeared online based on a report filed by Press Trust of India (PTI) titled “Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of jabs. PDF 319 KB
13 May 2022 Intimation under Reg 39 (3) of LODR PDF 498 KB
06 May 2022 Intimation under Reg 39 (3) of LODR PDF 324 KB
02 May 2022 Intimation under Reg 39 (3) of LODR PDF 236 KB
25 Apr 2022 Intimation under Reg 39 (3) of LODR PDF 387 KB
18 Apr 2022 Allotment of shares under Strides ESOP 2016 Plan PDF 170 KB
09 Apr 2022 Outcome of the Extraordinary General Meeting of the Company PDF 4.71 MB
07 Apr 2022 Proceedings of the Extraordinary General Meeting of the Company PDF 389 KB
29 Mar 2022 Strides announces Leadership changes PDF 453 KB
29 Mar 2022 Intimation under Regulation 30 of the SEBI Listing Regulations PDF 441 KB
24 Mar 2022 Intimation under Reg 39 (3) of LODR PDF 405 KB
21 Mar 2022 Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer’s COVID-19 Oral Treatment across 95 markets PDF 366 KB
17 Mar 2022 Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countrie PDF 453 KB
16 Mar 2022 Intimation under Reg 39 (3) of LODR PDF 264 KB
14 Mar 2022 Update on Proposed Preferential Issue PDF 989 KB
11 Mar 2022 Strides receives USFDA approval for Colchicine Tablets PDF 372 KB
21 Feb 2022 USFDA approval for Amantadine Hydrochloride Softgel Capsules PDF 378 KB
15 Feb 2022 Intimation under Reg 39 (3) of LODR PDF 301 KB
17 Feb 2022 Intimation regarding rescheduling of Extraordinary General Meeting PDF 243 KB
10 Feb 2022 Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations PDF 263 KB
10 Feb 2022 Outcome of Board Meeting - Disclosure under Regulation 30 of SEBI Listing Regulations PDF 356 KB
10 Feb 2022 Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2021 PDF 2.3 MB
09 Feb 2022 Intimation pursuant to Regulation 31A of the SEBI Listing Regulations PDF 409 KB
07 Feb 2022 Fund raising - Intimation under Regulation 29(2) of the SEBI Listing Regulations. PDF 274 KB
03 Feb 2022 Intimation under Reg 39 (3) of LODR PDF 314 KB
28 Jan 2022 SE Intimation PDF 315 KB
20 Jan 2022 Strides and its African subsidiary Universal Corporation partner with Medicines Patent Pool (MPP) to commercialize molnupiravir for the global markets PDF 499 KB
18 Jan 2022 Outcome of the Postal Ballot Notice dated November 10, 2021 PDF 5.8 MB
17 Jan 2022 Strides receives USFDA approval for Oseltamivir Phosphate for Oral Suspension PDF 377 KB
Date Title   Report

31 Dec 2021 Intimation under Reg 39 (3) of LODR PDF 428 KB
28 Dec 2021 Strides receives DCGI approval under EUA to commercialize Molnupiravir, an oral medication for Covid-19 PDF 228 KB
21 Dec 2021 Stelis Biopharma commissions its greenfield vaccine manufacturing facility at Bengaluru, India, successfully completes the CDSCO inspection for Drug Substance and Drug Product, and receives initial NOC to export 50 million doses of Russian Sputnik Light Vaccine PDF 253 KB
15 Dec 2021 Notice of Postal Ballot dated November 10, 2021 PDF 725 KB
10 Nov 2021 Intimation under Reg 31A of LODR – Board approval for Reclassification PDF 447 KB
10 Nov 2021 Intimation under Reg 30 of LODR – Postal Ballot Matters PDF 649 KB
10 Nov 2021 Intimation under PIT Regulations – Strides’ Fair Disclosure Code PDF 4.1 MB
10 Nov 2021 Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2021 PDF 4.1 MB
01 Nov 2021 Allotment of shares under Strides ESOP 2016 Plan PDF 157 KB
28 Oct 2021 Intimation under Reg 39 (3) of LODR PDF 393 KB
22 Oct 2021 SE Intimation PDF 463 KB
22 Oct 2021 Request received for reclassification of shareholding from ‘Promoter/ Promoter Group’ to ‘Public’ Category’ PDF 998 KB
22 Oct 2021 Intimation under Reg 39 (3) of LODR PDF 448 KB
21 Oct 2021 Strides announces completion of transaction to acquire manufacturing facility in the US along with basket of ANDAs from Endo International plc PDF 173 KB
12 Oct 2021 Intimation pursuant to Regulation 31A of the SEBl Listing Regulations – Approval received from BSE and NSE for reclassification of SeQuent Scientific Limited from ‘Promoter Group’ to ‘Public’ Category. PDF 509 KB
01 Oct 2021 Intimation under Regulation 30 of SEBI Listing Regulations regarding termination of Shareholders’ Agreement of May 16, 2016 PDF 292 KB
14 Sep 2021 SE Intimation PDF 385 KB
06 Sep 2021 SE Intimation PDF 408 KB
06 Sep 2021 SE Intimation PDF 456 KB
04 Sep 2021 Outcome of the 30th Annual General Meeting of the Company PDF 2.43 MB
03 Sep 2021 SE Intimation PDF 373 KB
03 Sep 2021 Proceedings of the 30th Annual General Meeting of the Company PDF 501 KB
11 Aug 2021 Notice of 30th Annual General Meeting and Annual Report for FY 2020-21 PDF 4.12 MB
06 Aug 2021 Stelis Biopharma - Q1 FY22 Investor Update PDF 1.83 MB
06 Aug 2021 Stelis Biopharma strengthens its Board with experienced industry leadership and diversity PDF 257 KB
06 Aug 2021 Stelis Biopharma appoints Mark W. Womack as the new CEO PDF 255 KB
06 Aug 2021 Outcome of Board Meeting – Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2021 PDF 1.76 MB
06 Aug 2021 Allotment of Shares under Strides ESOP Plan 2016 PDF 198 KB
06 Aug 2021 Strides inks definitive agreement with Endo to acquire its manufacturing facility in the US along with basket of ANDAs PDF 392 KB
04 Aug 2021 SE Intimation PDF 444 KB
26 Jul 2021 Intimation to Members about Annual General Meeting of the Company and Record Date for the purpose of Final Dividend PDF 352 KB
30 Jun 2021 Allotment of shares under Strides ESOP 2016 Plan PDF 356 KB
29 Jun 2021 Annual Secretarial Compliance Report for the year ended March 31, 2021 PDF 1.72 MB
28 Jun 2021 Strides announces successful completion of EU GMP inspection at Puducherry facility PDF 384 KB
25 Jun 2021 Disclosure of Related Party Transactions for the year ended March 31, 2021 PDF 441 KB
22 Jun 2021 Appointment of Chief Human Resource Officer PDF 243 KB
16 Jun 2021 SE Intimation PDF 247 KB
14 Jun 2021 Ennaid Therapeutics partners exclusively with Strides to manufacture life-saving oral Covid-19 Tablet PDF 476 KB
12 Jun 2021 Outcome of Postal Ballot – Re-appointment of Mr. Bharat Shah as an Independent Director of the Company PDF 2.96 MB
10 Jun 2021 SE intimation PDF 327 KB
27 May 2021 Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for the quarter and year ended March 31, 2021 PDF 1.06 MB
27 May 2021 Recommendation of Final Dividend for the financial year ended March 31, 2021 PDF 230 KB
27 May 2021 Grant of Options under Strides ESOP Plan 2016 PDF 174 KB
27 May 2021 Allotment of shares under Strides ESOP 2016 Plan PDF 202 KB
27 May 2021 TLC and Strides partner to launch Liposomal Amphotericin B in India PDF 485 KB
25 May 2021 Update on completion of Series C funding in Stelis PDF 277 KB
12 May 2021 SE Intimation - Notice of Postal Ballot PDF 457 KB
10 May 2021 Intimation on re-appointment of Independent Director of the Company PDF 263 KB
03 May 2021 SE Intimation PDF 263 KB
12 Apr 2021 Intimation pursuant to Regulation 31A of SEBl Listing Regulations PDF 233 KB
31 Mar 2021 SE Intimation PDF 566 KB
19 Mar 2021 RDIF and Stelis Biopharma partner to supply 200 million doses of the Sputnik V vaccine PDF 326 KB
19 Mar 2021 Stelis concludes US$ 195m Series B and Series C fund raise Significant interest from marquee long term investors PDF 439 KB
17 Mar 2021 Strides – Outcome of Postal Ballot – Relating to SeQuent Reclassification PDF 2.6 MB
15 Mar 2021 Strides receives USFDA approval for Potassium Chloride for Oral Solution PDF 402 KB
05 Mar 2021 SE Intimation PDF 196 KB
03 Mar 2021 Intimation under Reg 39 (3) of LODR PDF 319 KB
24 Feb 2021 Strides receives USFDA approval for Ibuprofen OTC Oral Suspension PDF 369 KB
12 Feb 2021 Strides receives USFDA approval for Prednisone Tablets PDF 307 KB
10 Feb 2021 SE Intimation - Notice of Postal Ballot PDF 612 KB
09 Feb 2021 Intimation under Reg 39 (3) of LODR PDF 322 KB
04 Feb 2021 Strides Outcome of Board Meeting PDF 2.4 MB
04 Feb 2021 Strides allotment of shares PDF 202 KB
04 Feb 2021 Strides Press Release - Relating to Stelis PDF 398 KB
25 Jan 2021 Strides receives USFDA approval for Ursodiol Capsules PDF 308 KB
22 Jan 2021 India Ratings upgrades Strides Pharma Science Limited to ‘IND A+’; Outlook Stable PDF 238 KB
15 Jan 2021 Strides receives USFDA approval for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets PDF 366 KB
08 Jan 2021 Aditya Puri joins as Advisor to the Strides Group & Director of Stelis Biopharma PDF 318 KB
Date Title   Report

18 Dec 2020 Strides receives USFDA approval for Oxybutynin Chloride Tablets PDF 364 KB
26 Nov 2020 Disclosure of Related Party Transactions for the half year ended September 30, 2020 PDF 540 KB
23 Nov 2020 Strides receives USFDA approval for Prednisone Tablets PDF 367 KB
12 Nov 2020 Receipt of NCLT Mumbai Bench Order PDF 226 KB
06 Nov 2020 Intimation under Reg 39 (3) of LODR PDF 787 KB
29 Oct 2020 Strides Outcome of BM Results PDF 7.61 MB
29 Oct 2020 Strides Allotment of shares under ESOP PDF 202 KB
29 Oct 2020 Strides Board Approval Sequent reclassification PDF 485 KB
29 Oct 2020 Strides Vivimed Merger Reg30 PDF 315 KB
20 Oct 2020 Strides receives USFDA approval for Ethacrynic Acid Tablets PDF 368 KB
22 Sep 2020 Strides receives USFDA approval for Butalbital, Acetaminophen, and Caffeine Tablets PDF 368 KB
16 Sep 2020 Intimation under Reg 39 (3) of LODR PDF 341 KB
15 Sep 2020 Intimation under Reg 39 (3) of LODR PDF 967 KB
14 Sep 2020 Disclosure under Reg 30 of SEBI LODR relating to Press Release dated Sep 14, 2020 PDF 331 KB
14 Sep 2020 Strides unveils SteriScience as its dedicated arm for sterile injectables PDF 1.19 MB
03 Sep 2020 Strides receives USFDA approval for Prednisone Tablets PDF 363 KB
31 Aug 2020 Strides Allotment of shares PDF 241 KB
21 Aug 2020 Strides AGM SEBI Results and Scrutinizer Report PDF 5.34 MB
21 Aug 2020 Strides receives USFDA approval for Ursodiol Tablets PDF 197 KB
20 Aug 2020 Strides Intimation of Proceeding of AGM PDF 250 KB
19 Aug 2020 Strides announces successful completion of UK MHRA inspection at Puducherry facility PDF 210 KB
05 Aug 2020 Strides Outcome of the BM Results PDF 2.26 MB
05 Aug 2020 Strides intimation allotment of shares PDF 102 KB
29 Jul 2020 Strides Book Closure for AGM PDF 149 KB
29 Jul 2020 Notice of 29th Annual General Meeting and Annual Report for FY 2019-2020 PDF 3.87 MB
15 Jul 2020 29th Annual General Meeting / Record date PDF 209 KB
09 Jul 2020 Strides receives USFDA approval for Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules PDF 309 KB
19 Jun 2020 NCLT Order of Blore Bench Merger of WoS PDF 168 KB
18 Jun 2020 Disclosure of Related Party Transactions for the year ended March 31, 2020 PDF 276 KB
10 Jun 2020 Intimation under Reg 39 (3) of LODR PDF 150 KB
02 Jun 2020 Strides receives USFDA approval for Triamcinolone Acetonide Ointment PDF 299 KB
22 May 2020 Strides SE Intimation PDF 143 KB
20 May 2020 Outcome of Board Meeting Results PDF 3.36 MB
20 May 2020 Outcome of Board Meeting - Final Dividend PDF 126 KB
20 May 2020 Allotment of shares under ESOP PDF 127 KB
20 May 2020 Grant of Stock Options PDF 970 KB
29 Apr 2020 Strides develops and commences export of Favipiravir Antiviral Tablets PDF 327 KB
20 Apr 2020 Strides receives USFDA approval for Flucytosine Capsules PDF 256 KB
02 Apr 2020 Strides provides updates as USFDA requests all manufacturers to withdraw Ranitidine products from the US Market PDF 283 KB
30 Mar 2020 Strides announces successful completion of US FDA inspection conducted in January 2020 at flagship facility in Bangalore PDF 256 KB
26 Mar 2020 EIR from USFDA on continued GMP status for the flagship facility in Bangalore PDF 148 KB
13 Mar 2020 Intimation under Reg 39 (3) of LODR PDF 614 KB
04 Mar 2020 Strides receives USFDA approval for Tetracycline Hydrochloride Capsules PDF 236 KB
21 Feb 2020 Outcome of NCLT Meeting PDF 661 KB
18 Feb 2020 Intimation under Reg 39 (3) of LODR PDF 911 KB
07 Feb 2020 Strides to acquire 18 ANDAs from Pharmaceutics International, Inc. PDF 300 KB
31 Jan 2020 Intimation of Investors / Analysts Meet PDF 230 KB
30 Jan 2020 SE Intimation Scheme of Amalgamation PDF 492 KB
30 Jan 2020 Outcome of Board Meeting Results PDF 4.16 MB
30 Jan 2020 SE Intimation allotment of shares - ESOP PDF 106 KB
29 Jan 2020 Intimation under Reg 39 (3) of LODR PDF 727 KB
28 Jan 2020 Strides Earnings Call Invite PDF 174 KB
24 Jan 2020 Strides announces the successful completion of US FDA inspection at its Alathur facility with “Zero 483 observations” PDF 269 KB
24 Jan 2020 USFDA tentative approval for Triamcinolone Acetonide Ointment PDF 169 KB
20 Jan 2020 Strides announces successful closure of the USFDA inspection at its manufacturing site in Florida, United States PDF 1.19 MB
17 Jan 2020 SPSL Intimation to SE Tribunal Meeting PDF 7.86 MB
16 Jan 2020 USFDA approval for Loratadine OTC Softgel Capsules PDF 178 KB
08 Jan 2020 Dr. R Ananthanarayanan appointed as the new CEO & Managing Director of Strides PDF 212 KB
08 Jan 2020 Press Release on appointment of new CEO & MD PDF 251 KB
08 Jan 2020 SE Intimation on appointment of new CEO & MD PDF 63 KB
08 Jan 2020 SE Intimation on KMP PDF 83 KB
08 Jan 2020 Intimation under Reg 39 (3) of LODR PDF 914 KB
Date Title   Report

24 Dec 2019 Intimation under Reg 39 (3) of LODR PDF 564 KB
19 Dec 2019 SE Intimation PDF 419 KB
17 Dec 2019 SE Intimation PDF 427 KB
11 Dec 2019 Intimation on Appointment of ID PDF 64 KB
05 Dec 2019 Intimation of Investor/ Analyst Day PDF 147 KB
04 Dec 2019 USFDA tentative approval for Diclofenac Potassium Softgel Capsules PDF 406 KB
27 Nov 2019 SE Intimation PDF 314 KB
25 Nov 2019 Outcome of Postal Ballot – CG to Stelis PDF 1.06 MB
22 Nov 2019 Disclosure of Related Party Transactions for the half year ended September 30, 2019 PDF 227 KB
08 Nov 2019 Strides announces relaunch of Ranitidine tablets (Rx) for the US Market PDF 402 KB
06 Nov 2019 Intimation SE Merger of WoS PDF 1.67 MB
04 Nov 2019 Strides’ Ranitidine Tablets 300 mg lots tested by USFDA are within the acceptable NDMA limits PDF 181 KB
25 Oct 2019 Outcome of Board Meeting of Oct 25, 19 - Allotment of shares PDF 421 KB
25 Oct 2019 Outcome of Board Meeting of Oct 25, 19_Grant of Options PDF 50 KB
25 Oct 2019 Outcome of Board Meeting of Oct 25, 19 - Unaudited results PDF 3.01 MB
25 Oct 2019 SPSL Earnings Call Intimation PDF 176 KB
23 Oct 2019 TGA, Australia announces Ranitidine test results PDF 421 KB
23 Oct 2019 EIR from USFDA on continued GMP status for formulation facility at Alathur PDF 146 KB
22 Oct 2019 SE Intimation of Postal Ballot and Evoting PDF 870 KB
04 Oct 2019 Update on Encumbrance by Promoters PDF 1.98 MB
27 Sep 2019 Strides receives USFDA approval for Solifenacin Succinate Tablets PDF 304 KB
27 Sep 2019 Further Updates on Ranitidine Tablets for the US Markets PDF 146 KB
25 Sep 2019 Update on Ranitidine tablets PDF 224 KB
20 Sep 2019 Strides Board approves incremental investments in Stelis PDF 316 KB
20 Sep 2019 Strides Board approves incremental investments in Stelis PDF 227 KB
20 Sep 2019 Grant of Options under Strides Employee Stock Option Plan 2016 PDF 52 KB
11 Sep 2019 Strides acquires strategic stake in Fairmed Healthcare AG in Europe PDF 320 KB
06 Sep 2019 SE Intimation PDF 302 KB
28 Aug 2019 SE Intimation PDF 196 KB
27 Aug 2019 Strides acquires USFDA approved manufacturing facility in the US PDF 349 KB
09 Aug 2019 Successful completion of US FDA inspection at its Alathur facility with "Zero 483 observations" PDF 1.4 MB
31 Jul 2019 Intimation on proceeding of 28th AGM – July 30, 2019 PDF 174 KB
31 Jul 2019 Outcome of 28th AGM – July 30, 2019 PDF 1.64 MB
31 Jul 2019 Update PDF 125 KB
29 Jul 2019 Strides Outcome of the BM PDF 3.19 MB
29 Jul 2019 SE Intimation Grant of Options PDF 55 KB
29 Jul 2019 Strides Outcome of the BM - Dividend PDF 57 KB
29 Jul 2019 SPSL 2019 Merger-Intimation to SE PDF 175 KB
29 Jul 2019 Strides JVin Hong Kong PDF 158 KB
29 Jul 2019 Strides Board Meeting Outcome PDF 3.18 MB
29 Jul 2019 Strides Outcome of the BM Interim Dividend PDF 57 KB
29 Jul 2019 SPSL Earnings Call Intimation PDF 175 KB
23 Jul 2019 SE Intimation PDF 1.7 MB
23 Jul 2019 EIR from USFDA on continued GMP status for the flagship facility in Bangalore PDF 132 KB
20 Jul 2019 Strides announces successful completion of US FDA inspection at its flagship facility in Bangalore PDF 217 KB
17 Jul 2019 Clarification on the Article appeared in Economic Times on July 17, 2019 PDF 333 KB
10 Jul 2019 SE Intimation PDF 1.72 MB
10 Jul 2019 SE Intimation PDF 1.80 MB
10 Jul 2019 Update on “Strides announces final closure of Arrow transaction" PDF 133 KB
05 Jul 2019 SE Intimation - Book closure intimation and Record date PDF 49 KB
05 Jul 2019 SE Intimation - AGM Notice and Annual Report for FY 18-19 PDF 4.13 MB
02 Jul 2019 Update relating to “USFDA classifies Strides Puducherry facility as Official Action Indicated (OAI)”. PDF 129 KB
01 Jul 2019 Update on “Strides to exit its investment in Arrow for AUD 394 Million" PDF 128 KB
19 Jun 2019 Intimation under Reg 39 (3) of LODR PDF 308 KB
10 Jun 2019 SE Intimation PDF 1.60 MB
08 Jun 2019 Disclosure of Related Party Transactions for the half year ended March 31, 2019 PDF 285 KB
10 May 2019 Audited Financial Results PDF 2.2 MB
10 May 2019 Declaration of Final Dividend PDF 117 KB
10 May 2019 SPSL Earnings Call Intimation PDF 175 KB
07 May 2019 SE Intimation PDF 1.7 MB
06 May 2019 USFDA classifies Strides Puducherry facility as Official Action Initiated (OAI) PDF 146 KB
03 May 2019 Vivimed Life Sciences Private Limited (VLSPL) issues voluntary recall of 19 lots of Losartan Pottasium Tablets in USA due to detection of trace amount of N-Nitriso-N-methyl-4-aminobutyric acid (NMBA) impurity. These lots were manufactured at VLSPL's Alathur facility prior to acquisition by Strides PDF 535 KB
12 Apr 2019 SE Intimation PDF 183 KB
05 Apr 2019 SE Intimation PDF 841 KB
05 Apr 2019 Intimation under Reg 39 (3) of LODR PDF 812 KB
04 Apr 2019 Strides pharma intimation on window closure PDF 89 KB
03 Apr 2019 SE Intimation PDF 250 KB
02 Apr 2019 Receipt of Establishment Inspection Report (EIR) from US FDA for Singapore facility PDF 997 KB
02 Apr 2019 Strides to launch Potassium Chloride Extended-Release Tablets in the US market PDF 997 KB
01 Apr 2019 Amendment to the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information PDF 350 KB
29 Mar 2019 SE Intimation PDF 1.6 MB
27 Mar 2019 SE Intimation PDF 302 KB
27 Mar 2019 SE Intimation Lachhman Dass PDF 280 KB
27 Mar 2019 USFDA approval for its greenfield oral dosage facility in Singapore PDF 170 KB
27 Mar 2019 Intimation under Reg 39 (3) of LODR PDF 290 KB
19 Mar 2019 SE Intimation PDF 334 KB
19 Mar 2019 Intimation under Reg 39 (3) of LODR PDF 322 KB
18 Mar 2019 SE Intimation PDF 1.2 MB
18 Mar 2019 SE Intimation - Lata Kapoor PDF 1.8 MB
15 Mar 2019 SE Intimation 2 PDF 927 KB
15 Mar 2019 SE Intimation PDF 312 KB
08 Mar 2019 SE Intimation PDF 227 KB
05 Mar 2019 SE Intimation PDF 1.7 MB
22 Feb 2019 SE Intimation PDF 208 KB
20 Feb 2019 SE Intimation PDF 1.1 MB
20 Feb 2019 USFDA approval for Ethosuximide Softgel Capsules PDF 187 KB
20 Feb 2019 Intimation under Reg 39 (3) of LODR PDF 1.02 MB
13 Feb 2019 USFDA approval for Triamcinolone Acetonide Cream PDF 181 KB
06 Feb 2019 EIR from USFDA on continued GMP status for the flagship facility in Bangalore PDF 177 KB
04 Feb 2019 SE Intimation PDF 302 KB
29 Jan 2019 Outcome of Board meeting PDF 2.03 MB
29 Jan 2019 Strides to exit its investment in Arrow PDF 328 KB
29 Jan 2019 Strides to acquire 80% stake in Pharmapar Inc. PDF 329 KB
29 Jan 2019 Strides to acquire 100% stake in Vensun Pharmaceuticals, Inc PDF 326 KB
29 Jan 2019 SPSL Earnings Call Intimation PDF 98 KB
25 Jan 2019 Strides to convert its 50:50 JV with Vivimed to 100% ownership PDF 371 KB
24 Jan 2019 SE Intimation PDF 235 KB
22 Jan 2019 SE Intimation PDF 377 KB
17 Jan 2019 SE Intimation PDF 253 KB
03 Jan 2019 SE Intimation - Rashmi Vyas PDF 590 KB
03 Jan 2019 SE Intimation - Nitha Shah PDF 366 KB
Date Title   Report

18 Dec 2018 Intimation under Reg 39 (3) of LODR PDF 1.79 MB
14 Dec 2018 Intimation under Reg 39 (3) of LODR PDF 865 KB